Who Supplies Mitomycin? Top Manufacturers & Their Global Buyers
India accounts for a significant share of global Mitomycin exports, with 213+ registered manufacturers shipping to buyers across 103+ countries — yet a handful of companies dominate the shipments. INTAS PHARMACEUTICALS LIMITED holds the largest share at 23.5% (export value: $1.9M). Close behind, MYLAN LABORATORIES LIMITED (22.9%, $1.9M). INTAS PHARMACEUTICALS LTD (6.8%, $558.1K). The Sankey diagram below maps every supplier's customer flow in detail. All figures are drawn from Indian Customs (DGFT) shipping bill records.
🏭 Market Analysis: Top Suppliers & Customer Networks
Comprehensive supplier network intelligence dashboard
Who Supplies Mitomycin? Top Manufacturers & Their Buyers
Flow of Mitomycin from leading Indian exporters to their key global customers
Supplier-Customer Network Analysis
Top Suppliers → Customer Networks
Mitomycin Supplier Network — Key Market Intelligence
The Mitomycin export market from India is led by INTAS PHARMACEUTICALS LIMITED, which alone commands a 23.5% share, shipping $1.9M worth of product across 46 shipments. The second-largest exporter, MYLAN LABORATORIES LIMITED, contributes $1.9M (22.9%) to the overall market. Combined, the top two suppliers alone account for 46.4% of all Mitomycin exports, indicating a relatively concentrated supply base.
Across all 213 tracked manufacturers, the total Mitomycin export value stands at $8.2M from 1.3K shipments. The market average shipment value is $6.1K. The single largest buyer relationship in terms of trade value is RX CROSSROADS 3PL LLC, receiving $1.2M worth of product.
The combined buyer network spans 14 named purchasing companies, including FOUNDATION CARE, B BRAUN MEDICAL INC, XXOWAXXIRIXXCO XXLIMITEDX, RX CROSSROADS 3PL LLC, RXCROSSROADS 3PL LLC and 9 others. These buyers represent pharmaceutical manufacturers, distributors, hospital procurement groups, and generic drug producers operating across multiple continents.
Market Analysis: Top Suppliers & Their Customer Networks
1INTAS PHARMACEUTICALS LIMITED
INTAS PHARMACEUTICALS LIMITED is the first-largest Mitomycin exporter from India, with a market share of 23.5% and a total export value of $1.9M across 46 shipments. Their average shipment value of $41.7K is above the market average of $6.1K, suggesting premium or bulk contract pricing.
INTAS PHARMACEUTICALS LIMITED serves 5 named buyers in our database. TO THE ORDER is the dominant customer, accounting for 54.5% of this supplier's tracked business. Top customers include:
• TO THE ORDER — $1.0M across 25 shipments (54.5% of this supplier's total exports)
• FOUNDATION CARE — $432.5K across 10 shipments (22.6% of this supplier's total exports)
• B BRAUN MEDICAL INC — $222.2K across 5 shipments (11.6% of this supplier's total exports)
• FOUNDATION CARE — $128.1K across 3 shipments (6.7% of this supplier's total exports)
• XXOWAXXIRIXXCO XXLIMITEDX — $88.9K across 2 shipments (4.6% of this supplier's total exports)
Key Insight: INTAS PHARMACEUTICALS LIMITED's per-shipment value of $41.7K is 581% above the market average of $6.1K, consistent with large-order contracts or value-added formulations.
2MYLAN LABORATORIES LIMITED
MYLAN LABORATORIES LIMITED is the second-largest Mitomycin exporter from India, with a market share of 22.9% and a total export value of $1.9M across 25 shipments. Their average shipment value of $74.6K is above the market average of $6.1K, suggesting premium or bulk contract pricing.
MYLAN LABORATORIES LIMITED serves 2 named buyers in our database. RX CROSSROADS 3PL LLC is the dominant customer, accounting for 65.5% of this supplier's tracked business. Top customers include:
• RX CROSSROADS 3PL LLC — $1.2M across 16 shipments (65.5% of this supplier's total exports)
• RXCROSSROADS 3PL LLC — $643.8K across 9 shipments (34.5% of this supplier's total exports)
Key Insight: MYLAN LABORATORIES LIMITED's per-shipment value of $74.6K is 1119% above the market average of $6.1K, consistent with large-order contracts or value-added formulations.
3INTAS PHARMACEUTICALS LTD
INTAS PHARMACEUTICALS LTD is the third-largest Mitomycin exporter from India, with a market share of 6.8% and a total export value of $558.1K across 7 shipments. Their average shipment value of $79.7K is above the market average of $6.1K, suggesting premium or bulk contract pricing.
INTAS PHARMACEUTICALS LTD serves 5 named buyers in our database. Business is spread across multiple buyers, reducing single-customer dependency. Top customers include:
• ACCORD HEALTHCARE IN — $245.8K across 3 shipments (44.0% of this supplier's total exports)
• KYOWA KIRIN CO LTD — $215.7K across 3 shipments (38.7% of this supplier's total exports)
• ACCORD HEALTHCARE PO — $57.6K across 1 shipments (10.3% of this supplier's total exports)
• XXcorXXHeaXXhcaXX B — $39.0K across 0 shipments (7.0% of this supplier's total exports)
• EUROFINS ANALYTICAL — $12 across 0 shipments (0.0% of this supplier's total exports)
Key Insight: INTAS PHARMACEUTICALS LTD's per-shipment value of $79.7K is 1203% above the market average of $6.1K, consistent with large-order contracts or value-added formulations.
4NAPROD LIFE SCIENCES PVT LTD
NAPROD LIFE SCIENCES PVT LTD is the fourth-largest Mitomycin exporter from India, with a market share of 4.1% and a total export value of $335.8K across 10 shipments. Their average shipment value of $33.6K is above the market average of $6.1K, suggesting premium or bulk contract pricing.
NAPROD LIFE SCIENCES PVT LTD serves 2 named buyers in our database. ATLANTA MEDICARE CO. LTD. is the dominant customer, accounting for 55.7% of this supplier's tracked business. Top customers include:
• ATLANTA MEDICARE CO. LTD. — $187.1K across 6 shipments (55.7% of this supplier's total exports)
• PHARMACIE CENTRALE DES HOPITAUX (P — $148.7K across 4 shipments (44.3% of this supplier's total exports)
Key Insight: NAPROD LIFE SCIENCES PVT LTD's per-shipment value of $33.6K is 449% above the market average of $6.1K, consistent with large-order contracts or value-added formulations.
5EUGIA PHARMA SPECIALITIES LIMITED
EUGIA PHARMA SPECIALITIES LIMITED is the fifth-largest Mitomycin exporter from India, with a market share of 4.0% and a total export value of $329.1K across 8 shipments. Their average shipment value of $41.1K is above the market average of $6.1K, suggesting premium or bulk contract pricing.
EUGIA PHARMA SPECIALITIES LIMITED serves 2 named buyers in our database. EUGIA US LLC is the dominant customer, accounting for 73.7% of this supplier's tracked business. Top customers include:
• EUGIA US LLC — $242.5K across 6 shipments (73.7% of this supplier's total exports)
• EUGIA US LLC — $86.6K across 2 shipments (26.3% of this supplier's total exports)
Key Insight: EUGIA PHARMA SPECIALITIES LIMITED's per-shipment value of $41.1K is 572% above the market average of $6.1K, consistent with large-order contracts or value-added formulations.
6NAPROD LIFE SCIENCES PRIVATE LIMITED
NAPROD LIFE SCIENCES PRIVATE LIMITED is the fifth-largest Mitomycin exporter from India, with a market share of 3.9% and a total export value of $316.3K across 19 shipments. Their average shipment value of $16.6K is above the market average of $6.1K, suggesting premium or bulk contract pricing.
NAPROD LIFE SCIENCES PRIVATE LIMITED serves 5 named buyers in our database. Business is spread across multiple buyers, reducing single-customer dependency. Top customers include:
• PHARMACIE CENTRALE DES HOPITAUX (P — $129.9K across 8 shipments (41.1% of this supplier's total exports)
• PHARMACIE CENTRALE DES HOPITAUX (P — $73.4K across 4 shipments (23.2% of this supplier's total exports)
• ATLANTA MEDICARE CO. LTD. — $50.7K across 3 shipments (16.0% of this supplier's total exports)
• ATLANTA MEDICARE CO. LTD. — $38.9K across 2 shipments (12.3% of this supplier's total exports)
• I & C (HONGKONG) LIM — $23.4K across 1 shipments (7.4% of this supplier's total exports)
Key Insight: NAPROD LIFE SCIENCES PRIVATE LIMITED's per-shipment value of $16.6K is 172% above the market average of $6.1K, consistent with large-order contracts or value-added formulations.
From Indian Factories to Global Pharmacies — How Mitomycin Flows
Once Mitomycin leaves the manufacturing plants of companies like INTAS PHARMACEUTICALS LIMITED and MYLAN LABORATORIES LIMITED, it travels to 5 destination markets with a combined import value of $8.2M. United States absorbs the largest share at 63.5% ($5.2M), followed by Algeria (7.5%) and Thailand (5.2%).
In United States — the top destination — named importers include RX CROSSROADS 3PL LLC, RXCROSSROADS 3PL LLC, FOUNDATION CARE. In Algeria, key buyers are PHARMACIE CENTRALE DES HOPITAUX (PC, PHARMACIE CENTRALE DES HOPITAUX, PHARMACIE CENTRALE DES HOPITAUX (P.
This geographic spread reflects Mitomycin's role as an essential active pharmaceutical ingredient (API) and finished dosage form — sourced primarily from India due to its cost-competitive, WHO-compliant manufacturing base. The Sankey diagram below maps these destination countries to their named importers in detail.
🌍 Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Where Does Mitomycin Go? Top Importing Countries & Their Buyers
Trade flow of Mitomycin exports from India — top destination countries and the named companies importing it
Geographic Market Flow Analysis
Top Countries → Global Importers
Market Analysis: Top Importing Countries & Their Importers
1United States
United States ranks as the first-largest destination for Mitomycin imports from India, with a total trade value of $5.2M across 57 shipments — representing a 63.5% share of all Mitomycin exports. The average shipment value of $90.9K is above the global average of $6.1K, indicating high-value procurement contracts or branded formulations. This market is served by 8 tracked buyers.
Named Mitomycin importers in United States: RX CROSSROADS 3PL LLC is the largest buyer, accounting for 34.3% ($1.8M) of this market's total imports.
• RX CROSSROADS 3PL LLC — $1.8M (34.3% of United States's total)
• RXCROSSROADS 3PL LLC — $643.8K (12.4% of United States's total)
• FOUNDATION CARE — $432.5K (8.3% of United States's total)
Key Insight: United States's per-shipment average of $90.9K (1385% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
United States is a key market for Mitomycin imports from India.
2Algeria
Algeria ranks as the second-largest destination for Mitomycin imports from India, with a total trade value of $611.7K across 9 shipments — representing a 7.5% share of all Mitomycin exports. The average shipment value of $68.0K is above the global average of $6.1K, indicating high-value procurement contracts or branded formulations. This market is served by 3 tracked buyers.
Named Mitomycin importers in Algeria: PHARMACIE CENTRALE DES HOPITAUX (PC is the largest buyer, accounting for 63.7% ($389.6K) of this market's total imports.
• PHARMACIE CENTRALE DES HOPITAUX (PC — $389.6K (63.7% of Algeria's total)
• PHARMACIE CENTRALE DES HOPITAUX — $148.7K (24.3% of Algeria's total)
• PHARMACIE CENTRALE DES HOPITAUX (P — $73.4K (12.0% of Algeria's total)
Key Insight: Algeria's per-shipment average of $68.0K (1011% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Algeria is a key market for Mitomycin imports from India.
3Thailand
Thailand ranks as the third-largest destination for Mitomycin imports from India, with a total trade value of $427.5K across 13 shipments — representing a 5.2% share of all Mitomycin exports. The average shipment value of $32.9K is above the global average of $6.1K, indicating high-value procurement contracts or branded formulations. This market is served by 2 tracked buyers.
Named Mitomycin importers in Thailand: ATLANTA MEDICARE CO LTD is the largest buyer, accounting for 52.9% ($226.0K) of this market's total imports.
• ATLANTA MEDICARE CO LTD — $226.0K (52.9% of Thailand's total)
• ATLANTA MEDICARE CO. LTD. — $149.1K (34.9% of Thailand's total)
Key Insight: Thailand's per-shipment average of $32.9K (437% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Thailand is a key market for Mitomycin imports from India.
4Japan
Japan ranks as the fourth-largest destination for Mitomycin imports from India, with a total trade value of $322.0K across 5 shipments — representing a 3.9% share of all Mitomycin exports. The average shipment value of $64.4K is above the global average of $6.1K, indicating high-value procurement contracts or branded formulations. This market is served by 2 tracked buyers.
Named Mitomycin importers in Japan: KYOWA KIRIN CO LTD is the largest buyer, accounting for 67.0% ($215.7K) of this market's total imports.
• KYOWA KIRIN CO LTD — $215.7K (67.0% of Japan's total)
• XXOWAXXIRIXXCO XXLIMITEDX — $88.9K (27.6% of Japan's total)
Key Insight: Japan's per-shipment average of $64.4K (952% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Japan is a key market for Mitomycin imports from India.
5Canada
Canada ranks as the fifth-largest destination for Mitomycin imports from India, with a total trade value of $245.8K across 0 shipments — representing a 3.0% share of all Mitomycin exports. The average shipment value of $245.8K is above the global average of $6.1K, indicating high-value procurement contracts or branded formulations.
Key Insight: Canada's per-shipment average of $245.8K (3917% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Canada is a key market for Mitomycin imports from India.
People Also Ask — Mitomycin Supplier & Trade Network
Who are the top suppliers of Mitomycin from India?+
Which companies buy Mitomycin from Indian manufacturers?+
Where does Mitomycin exported from India go?+
What is the market share of the top Mitomycin supplier from India?+
What is the average shipment value for Mitomycin exports from India?+
Is Mitomycin manufactured in India and exported globally?+
Which country imports the most Mitomycin from India?+
Who are the buyers of Mitomycin in Algeria?+
How concentrated is the Mitomycin supplier market in India?+
How do I find verified buyers for Mitomycin in specific countries?+
Mitomycin Trade Network — Key Takeaways
- 1INTAS PHARMACEUTICALS LIMITED is India's dominant Mitomycin exporter with a 23.5% market share and $1.9M in total exports — making it the single most important sourcing entity in this market.
- 2The top 213 suppliers collectively account for 65.2% of all tracked Mitomycin exports, with a combined trade value of $8.2M.
- 3United States is the largest destination market, absorbing 63.5% of India's Mitomycin exports ($5.2M). Algeria (7.5%) and Thailand (5.2%) follow.
- 4With 1.3K total shipments averaging $6.1K each, the Mitomycin export trade from India reflects both bulk API supply and finished dosage form distribution.
- 5Verified buyers across the network include FOUNDATION CARE, B BRAUN MEDICAL INC, RX CROSSROADS 3PL LLC, RXCROSSROADS 3PL LLC — representing a diverse base of pharmaceutical importers, distributors, and generic drug manufacturers globally.
Network Overview
Supplier Network
Country Network
Network Insights
Top supplier: 5 customers
6 suppliers → 103 countries
Network value: $8.2M
Related Analysis
Market Intelligence
Latest developments and market context
Detailed market intelligence for Mitomycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Network Construction: Supplier-to-buyer trade relationships constructed from verified shipment pairs in Indian Customs (DGFT) records for Mitomycin.
- 2.Flow Mapping: 213 Indian manufacturers mapped to their international buyer networks using consignee name normalization.
- 3.Value Aggregation: Trade value per supplier-buyer link aggregated from 1,333 individual shipment records. Values are FOB in USD.
- 4.Geographic Clustering: Buyer networks clustered across 103 destination countries to identify geographic concentration patterns.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,333 Verified Shipments
213 manufacturers in network
Expert-Reviewed
By pharmaceutical trade specialists